糖尿病和动脉粥样硬化的潜在靶标——FABP4(aP2)  

A potential target for diabetes and atherosclerosis:FABP4(aP2)

作　　者：闫桂蕊[1] 张小东[1] 蔡海燕[1] 朱维良[1] 王贺瑶[1] 

机构地区：[1]中国科学院上海药物研究所,上海201203

出　　处：《生命科学》2009年第2期270-275,共6页Chinese Bulletin of Life Sciences

基　　金："863"项目(2007AA02Z301);上海药物研究所基础研究项目(07G603L056)

摘　　要：脂肪细胞型脂肪酸结合蛋白(A-FABP/FABP4/aP2/ALBP)作为脂肪酸结合蛋白家族中的一员,在脂肪细胞和巨噬细胞中高表达。在鼠及人的肥胖个体中FABP4表达均增加。FABP4基因缺陷可改善胰岛素抵抗,并抑制动脉粥样硬化的发生发展。FABP4抑制剂减小了动物体内动脉硬化斑块的大小且提高了胰岛素敏感性。FABP4已经成为治疗糖尿病和动脉粥样硬化的重要潜在靶标。Adipocyte fatty-acid-binding protein （A-FABP/FABP4/aP2/ALBP）, a member of the intracellular fatty acid binding proteins （FABPs）, is primarily located in adipocytes and macrophages. It has been shown that loss of Fabp4 improved insulin resistance and ameliorated atherosclerosis in Fabp4 deficient mice. In addition, inhibitors of FABP4 reduced the size of atherosclerotic lesions and increased insulin sensitivity. Thus, FABP4 has been viewed as a potential therapeutic target in treatment of diabetes and atherosclerosis.

关 键 词：脂肪细胞型脂肪酸结合蛋白 糖尿病 动脉粥样硬化 药物靶标 

分 类 号：Q513[生物学—生物化学] R587.1[医药卫生—内分泌]